COMP <GO>
ABT vs PFE // DIVIDEND YIELD & FCF PAYOUT SAFETY
Abbott Laboratories (NYSE) VS. Pfizer Inc. (NYSE) • 15-METRIC TALLY: ABT 9
— PFE 5
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: ABT
LAST: $110.16 (+3.73%) • MKT CAP: $183.77B
dividend-safety
2.27%
LAST: $30.67 (+0.49%) • MKT CAP: $173.95B
dividend-safety
0.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ABT VS. PFE)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | ABT | PFE | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 56.40% | 74.30% | -17.90 | PFE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 11.90% | 5.10% | +6.80 | ABT | /roic <GO> |
| EV/EBITDA & P/E Valuation | 18.4x | 19.7x | -1.30 | ABT | /valuation <GO> |
| Free Cash Flow Yield | 4.09% | 5.32% | -1.23 | PFE | /fcf-yield <GO> |
| Operating Margin | 18.20% | 15.10% | +3.10 | ABT | /operating-margins <GO> |
| Net Profit Margin | 14.70% | 12.40% | +2.30 | ABT | /net-margins <GO> |
| Revenue Growth (YoY) | 5.70% | -1.60% | +7.30 | ABT | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 2.27% | 0.00% | +2.27 | ABT | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 4.36 | 2.10 | +2.26 | ABT | /balance-sheet <GO> |
| Piotroski F-Score Quality | 8/9 | 7/9 | +1.00 | ABT | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 58.5 | 63.6 | -5.10 | PFE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.99 | 1.05 | -0.06 | PFE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 25.8x | 20.5x | +5.30 | PFE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $183.77B | $173.95B | $9.81B | ABT | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | ABT REV | PFE REV | ABT GROSS % | PFE GROSS % | ABT FCF | PFE FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $44.33B | $62.58B | 56.4% | 74.3% | $7.39B | $9.07B |
| FY 2024 | $41.95B | $63.63B | 55.4% | 71.9% | $6.35B | $9.84B |
| FY 2023 | $40.11B | $50.91B | — | — | $5.46B | $6.41B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ABT // BETA 0.99
PFE // BETA 1.05